# Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma

> **NCT00305812** · PHASE2 · COMPLETED · sponsor: **NCIC Clinical Trials Group** · enrollment: 51 (actual)

## Conditions studied

- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **DRUG:** dexamethasone
- **DRUG:** lenalidomide
- **DRUG:** melphalan

## Key facts

- **NCT ID:** NCT00305812
- **Lead sponsor:** NCIC Clinical Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03-09
- **Primary completion:** 2008-06-30
- **Final completion:** 2008-06-30
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2023-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00305812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00305812, "Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00305812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*